Antineoplastics
1
Reactions 431 - 12 Dec 1992 Antineoplastics Secondary cancers in patients with Hodgkin’s disease: incidence study The risk of developing a secondary cancer was associated with various treatment- and patient-related factors in an analysis of 12 411 patients from the International Database on Hodgkin’s Disease who had survived at least 1 year post- treatment. There were 367 cases of solid tumour Cancers of the salivary gland, bronchus, pleura, skin (other than melanoma), small intestine (males only), bone (males only) and breast (females only) occurred at significantly higher rates than in the general population. An increased risk of solid tumour was associated with age > 40 years and extended field radiotherapy given alone or in combination with antineoplastic therapy. The cumulative incidence increased from 3.1% at 10 years after start of treatment for Hodgkin’s disease to 6.2% after 15 years. Acute leukaemias and myelodysplastic disorders numbered 158, again occurring at a significantly higher rate than in the general population. Age > 40 years and antineoplastic therapy with MOPP (chlormethine, vincristine, procarbazine and prednisone, or minor variations) either alone or with radiotherapy correlated strongly with an increased risk of secondary leukaemia. The third group of secondary cancers was non-Hodgkin’s lymphoma of which there were 106 cases associated significantly with age > 30 years, radiotherapy combined with non-MOPP chemotherapy (mainly daunorubicin-containing regimens) and any treatment for relapse. The cumulative incidence rates were 1.4 and 1.6% for leukaemias and non-Hodgkin’s lymphoma respectively, at 15 years after the start of treatment Henry-Amar M. Second cancer after the treatment for Hodgkin’s disease: a report from the International Database on Hodgkin’s disease. Annals of Oncology 3 (Suppl. 4): 117-128, Sep 1992 - France 800169453 1 Reactions 12 Dec 1992 No. 431 0114-9954/10/0431-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 431 - 12 Dec 1992
Antineoplastics
Secondary cancers in patients with Hodgkin’sdisease: incidence study
The risk of developing a secondary cancer was associatedwith various treatment- and patient-related factors in ananalysis of 12 411 patients from the International Database onHodgkin’s Disease who had survived at least 1 year post-treatment. There were 367 cases of solid tumour Cancers ofthe salivary gland, bronchus, pleura, skin (other thanmelanoma), small intestine (males only), bone (males only)and breast (females only) occurred at significantly higher ratesthan in the general population. An increased risk of solidtumour was associated with age > 40 years and extended fieldradiotherapy given alone or in combination with antineoplastictherapy. The cumulative incidence increased from 3.1% at 10years after start of treatment for Hodgkin’s disease to 6.2%after 15 years. Acute leukaemias and myelodysplasticdisorders numbered 158, again occurring at a significantlyhigher rate than in the general population. Age > 40 years andantineoplastic therapy with MOPP (chlormethine, vincristine,procarbazine and prednisone, or minor variations) either aloneor with radiotherapy correlated strongly with an increased riskof secondary leukaemia. The third group of secondary cancerswas non-Hodgkin’s lymphoma of which there were 106 casesassociated significantly with age > 30 years, radiotherapycombined with non-MOPP chemotherapy (mainlydaunorubicin-containing regimens) and any treatment forrelapse. The cumulative incidence rates were 1.4 and 1.6% forleukaemias and non-Hodgkin’s lymphoma respectively, at 15years after the start of treatmentHenry-Amar M. Second cancer after the treatment for Hodgkin’s disease: a reportfrom the International Database on Hodgkin’s disease. Annals of Oncology 3(Suppl. 4): 117-128, Sep 1992 - France 800169453
1
Reactions 12 Dec 1992 No. 4310114-9954/10/0431-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
